SuanFarma-Header SuanFarma-Header

X

Find FDA Investigational New Drug (IND) Submissions for Musculoskeletal

Loading...

All Data

Filters Filter
×
FILTER:
filter Country
    filter News Type
      filter Company
        filter Product Type
          filter Deal Size

            Active Filter(s):

            Product Type

            Companies

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Lead Product(s): Antibody-Oligonucleotide Conjugates

            Therapeutic Area: Musculoskeletal Product Name: Undisclosed

            Highest Development Status: IND Enabling Product Type: Large molecule

            Partner/Sponsor/Collaborator: RTW Investments

            Deal Size: $100.0 million Upfront Cash: Undisclosed

            Deal Type: Series C Financing May 26, 2020

            Details:

            The funds will enable Avidity to advance Company's growing proprietary portfolio of multiple programs, including Its AOC treatment of myotonic dystrophy type I, to treat serious muscle disorder.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Lead Product(s): Diclofenac Epolamine

            Therapeutic Area: Musculoskeletal Product Name: Undisclosed

            Highest Development Status: IND Enabling Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 19, 2020

            Details:

            FDA agreed that it is reasonable for Virpax to pursue a 505(b)(2) New Drug Application (NDA) for Epoladerm™, which is an abbreviated approval pathway allowing Virpax to reference safety and efficacy data of a reference listed drug.